In Alzheimer’s disease (AD), impaired lipid metabolism contributes to Aβ aggregation and tau pathology, with cholesterol modulating APP processing and ApoE4 impairing Aβ clearance (Rajmohan and Reddy, 2017). This evidence concerns the gene APP and Alzheimer disease.